ONC201 + dexamethasone

ONC201 + dexamethasone is a **combination therapy** currently investigated for relapsed/refractory multiple myeloma and hematologic malignancies. ONC201, also known as dordaviprone, is a first-in-class, orally bioavailable imipridone and a selective dopamine receptor D2 antagonist that activates the integrated stress response (ISR) pathway, leading to anti-tumor activity. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant activities, widely used as a backbone corticosteroid in multiple myeloma regimens. The combination leverages ONC201's stress-activated cytotoxicity and dexamethasone's immunomodulatory and cytotoxic effects. Preclinical studies indicate synergistic antitumor activity and minimal toxicity, making the combination promising for difficult-to-treat cancer types[1][2][3][5][6].

Other names

dordaviprone + dexamethasone